SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

DexCom, Inc. (DXCM) News

Track canonical SquawkNews coverage tagged to DXCM, DexCom, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol DXCM Asset equity Sector Markets 90 days 18 Last 89.8 Updated Jul 31, 2026, 02:05 PM UTC Open live news feed
H AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Nasdaq Composite gaining around 50 points on Friday. Shares of AXT Inc (NASDAQ: AXTI ) rose sharply after the company reported better-than-expected second-quarter financial results and is EARNINGS | Jul 31, 2026, 02:05 PM UTC H DXCM Raises Guidance After Q2 Beat DXCM beats Q2 estimates and raises guidance EQUITY | Jul 31, 2026, 12:12 PM UTC H DXCM Q2 EPS $0.70 vs. est. $0.61; Q2 revs rose 13% Y/y to $1.31B vs. est. $1.29B; raises midpoint of 2026 revenue guidance to $5.18-$5.25B, DXCM Q2 EPS $0.70 vs. est. $0.61; Q2 revs rose 13% Y/y to $1.31B vs. est. $1.29B; raises midpoint of 2026 revenue guidance to $5.18-$5.25B, up 11-13% and said expects 2026 non-GAAP gross profit margin of about 64%; Q2 sa EARNINGS | Jul 30, 2026, 08:14 PM UTC H DXCM Q2 EARNINGS • Adjusted EPS of $0.70 beating expectations of $0.61 • Revenue of $1.31B beating expectations of $1.29B • A DXCM Q2 EARNINGS • Adjusted EPS of $0.70 beating expectations of $0.61 • Revenue of $1.31B beating expectations of $1.29B • Adjusted operating income of $328.3M beating expectations of $285.5M • Adjus EARNINGS | Jul 30, 2026, 08:07 PM UTC H DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est DexCom (NASDAQ: DXCM ) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate. EARNINGS | Jul 30, 2026, 08:02 PM UTC H Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7. Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.5%, RIVN +/-7.9%, NXT +/-16.8%, MTZ +/-14.6%, AJG +/-7.2%, GH +/-14.1%, CTVA +/- EARNINGS | Jul 30, 2026, 05:58 PM UTC H Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I EARNINGS | Jul 28, 2026, 01:35 PM UTC L BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate MMED @ UBS EQUITY | Jul 28, 2026, 11:50 AM UTC L BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS EQUITY | Jul 28, 2026, 11:47 AM UTC H DXCM Earnings preview - continue to see DXCM as possessing one of the most attractive earnings growth algorithms in Medtech @ DBAB DXCM Earnings preview - continue to see DXCM as possessing one of the most attractive earnings growth algorithms in Medtech @ DBAB EARNINGS | Jul 23, 2026, 12:36 PM UTC L DXCM US FDA - selects DexCom as first tempo pilot participant for glucose health program - To select up to Ten tempo pilot participants per DXCM US FDA - selects DexCom as first tempo pilot participant for glucose health program - To select up to Ten tempo pilot participants per access model clinical use area REGULATION | Jul 22, 2026, 06:11 PM UTC L DexCom selected by FDA as first participant in TEMPO pilot The U.S. Food and Drug... REGULATION | Jul 22, 2026, 06:06 PM UTC L BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC EQUITY | Jul 21, 2026, 12:24 PM UTC H What You Missed On Wall Street On Thursday The major averages closed broadly lower amid a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Earnings season has started off strong this week, as more than 87% of the 40 S&P 500 RATES | Jul 16, 2026, 08:25 PM UTC H Midday Fly By: UnitedHealth, United Airlines, GE Aersopace report Q2 beats The Dow Jones Industrial Average was higher near noon while the S&P 500 and Nasdaq were lower as investors digest a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Markets continue MACRO | Jul 16, 2026, 04:10 PM UTC L DXCM - DexCom Receives Health Canada Authorization For DexCom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Se DXCM - DexCom Receives Health Canada Authorization For DexCom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes Link To Press Release GEOPOLITICS | Jul 13, 2026, 08:53 PM UTC L Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did DexCom, Inc. Insiders Breach their Fiduciary Duties EQUITY | Jul 03, 2026, 04:27 PM UTC M DXCM Advances Glucose Biosensing Dexcom further advances its vision of glucose biosensing for all EQUITY | Jun 23, 2026, 01:00 PM UTC